Article Sidebar

Download
PDF

Main Article Content

Abstract

 
RÉSUMÉ
Introduction. La pandémie à COVID-19 a conduit à l’avènement de diffèrent vaccins dont il reste encore à évaluer les effets secondaires de ces vaccins. Le but de cette étude était d’examiner les facteurs associés à l’apparition des effets secondaires après la vaccination. Méthodologie. Nous avons mené une étude transversale auprès chez les participants après avoir la réception de la première dose de vaccin contre l’infection à COVID -19. Les participants volontaires ont été questionnés après les 72 heures premières heures après la vaccination sur les effets secondaires cliniques ressentis. L’analyse des facteurs associés aux effets secondaires a porté sur le type de vaccin, les facteurs sociodémographiques et médicaux. L’Odds ratio avec un intervalle de confiance a été utilisé pour mesurer ces associations. Résultats. L’étude a porté sur 462 sujets répartis entre trois sites de vaccination à Bamako. La tranche d’âge la plus représentée a été les moins de 30 ans, (275/462) soit 59,52% et le sexe féminin a été majoritaire soit (265/462) 57,36 % et (262/462) soit 56,70% des participants avaient un indice de masse corporelle normal. La majorité de nos participants avaient reçu un vaccin à adénovirus (186/462) soit 40,30 %. Nous avons trouvé que (256/462) soit 55,40% de nos sujets ont présenté des effets secondaires le premier jour de la vaccination et l’apparition était liée au type de vaccin. Le signe le plus fréquent a été la douleur du site d’injection (177/462) soit 55,62%. Conclusion. Les effets secondaires des vaccins contre COVID-19 sont liés au type de vaccins et les signes sont le plus souvent mineurs.
ABSTRACT
Introduction. The COVID-19 pandemic has led to the advent of different vaccines, the side effects of which have yet to be assessed. The aim of this study is to examine the factors associated with the occurrence of side effects after vaccination. Methodology. We conducted a cross-sectional study among participants after receiving the first dose of vaccine against COVID-19 infection. Voluntary participants were questioned after the first 72 hours after vaccination about the clinical side effects experienced. The analysis of factors associated with side effects focused on the type of vaccine, sociodemographic and medical factors. The odds ratio with a confidence interval was used to measure these associations. Results. The study was carried out on 462 subjects distributed between three vaccination sites in Bamako. The most represented age group was persons aged 30 years or less (275/462) or 59.52%. Most persons were women (265/462) or 57.36 %. More over, (262/462) or 56.70% of participants had a normal body mass index. The most common vaccine was an adenovirus vaccine (186/462) or 40.30%. We found that (256/462) or 64.3% of subjects experienced side effects after receiving the first dose and the appearance was related to the type of vaccine. The most common side effect was pain at the injection site (177/462) or 55.6%. Conclusion. The side effects of vaccines against COVID-19 are more related to the type of vaccines and the signs are most often minor.

Keywords

Side effect Covid-19 Vaccine pandemic Adenovirus messenger RNA vaccination site Effet secondaire Covid-19 Vaccin pandémie Adénovirus

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

How to Cite
Tounkara M, Coulibaly S. L, Diarra A, Diallo M, Samake S, Sow F, Sissoko F, Tolofoudie M, Koumare M, Kamissoko B, Diallo B, Telly N, & Sangho O. (2023). Effets Secondaires Cliniques après l’Administration de la Première Dose de Vaccin contre la COVID-19 à Bamako. HEALTH SCIENCES AND DISEASE, 24(8). https://doi.org/10.5281/hsd.v24i8.4673
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Bogdanov G, Bogdanov I, Kazandjieva J, Tsankov N. Cutaneous adverse effects of the available COVID-19 vaccines. Clin Dermatol. 2021 May-June;39(3):523-31.
  2. Feraoun Y, Maisonnasse P, Le Grand R, Beignon A-S. COVID-19, des vaccins à la vitesse de l'eclair. medecine/sciences. 2021 2021. 37(8-9), 759-772.
  3. Le T. T. CJP, Chen R., Mayhew S. Evolution of the COVID-19 vaccine development landscape. Nature Reviews Drug Discovery 2020 07 Septembre 2020;19(6):2.
  4. Petousis-Harris H. Assessing the Safety of COVID-19 Vaccines: A Primer. Drug Saf. 2020 Dec;43(12):1205-10.
  5. Wouters OJ, Shadlen KC, Salcher-Konrad M, Pollard AJ, Larson HJ, Teerawattananon Y, et al. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet. 2021 Mar 13;397(10278):1023-34.
  6. McNeil MM, Weintraub ES, Duffy J, Sukumaran L, Jacobsen SJ, Klein NP, et al. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol. 2016 Mar;137(3):868-78.
  7. Aitnasser K SH, Moubachir H. . Les effets secondaires du vaccin COVID 19 chez la population du sud du Maroc. . Rev Malad Respir Actual. 2022 Jan 2022;14(1):2.
  8. Sah R SS, Mehta R, Sah SK, Rabaan AA, Dhama K, et al. AZD1222 (Covishield) vaccination for COVID-19: Experiences, challenges, and solu-tions in Nepal. Travel Med Infect Dis. 2021 March - April 2021;40.
  9. Rutschman, A. S. (2021). The COVID-19 vaccine race: Intellectual property, collaboration (s), nationalism and misinformation. Wash. UJL & Pol'y, 64, 167. accssed date May 25. 2023.
  10. Washrawirul C, Triwatcharikorn J, Phannajit J, Ullman M, Susantitaphong P, Rerknimitr P. Global prevalence and clinical manifestations of cutaneous adverse reactions following COVID-19 vaccination: A systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2022 Nov;36(11):1947-68.
  11. Food, U. S. (2021). Drug Administration (FDA). Janssen. FDA Briefing Document: Johnson &Johnson/Janssen COVID-19 Vaccine. Vaccines and Related Biological Products Advisory Committee Meeting. FDA web site. Accessed date May25, 2023.
  12. Hoffmann MA, Wieler HJ, Enders P, Buchholz HG, Plachter B. Age- and Sex-Graded Data Evaluation of Vaccination Reactions after Initial Injection of the BNT162b2 mRNA Vaccine in a Local Vaccination Center in Germany. Vaccines (Basel). 2021 Aug 16;9(8).
  13. Solomon Y ET, Mekasha B, Assefa W. COVID-19 Vaccine: Side Effects After the First Dose of the Oxford AstraZeneca Vaccine Among Health Professionals in Low-Income Country: Ethiopia. J Multidiscip Healthc. 2021;14:9.
  14. MN Z. Unfolding the Mild to Moderate Short-Term Side Effects of Four COVID-19 Vaccines Used in Bahrain: A Cross-Sectional Study. Vaccines 2021;9(11):12.
  15. Wu S, Huang J, Zhang Z, Wu J, Zhang J, Hu H, et al. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Lancet Infect Dis. 2021 Dec;21(12):1654-64.
  16. Bekkali N AT, Lengellé C, Estève E. Éruption eczématiforme après le vaccin par Pfizer-BioNTech COVID-19 [Eczematiform eruption after Pfizer-BioNTech COVID-19 vaccine. Elsevier Public Health Emergency Collection; Therapie. 2021 2021 Jul-Aug;76(4):2.
  17. Mori M, Yokoyama A, Shichida A, Sasuga K, Maekawa T, Moriyama T. Impact of Sex and Age on mRNA COVID-19 Vaccine-Related Side Effects in Japan. Microbiol Spectr. 2022 Dec 21;10(6):e0130922.
  18. Adhikari P AK, Gauli B., Sitaula D. Acceptance of COVID-19 vaccine and pattern of side effects in Nepalese context: a postvaccine cross-sectional study among health care workers in a tertiary care HOSPITAL. Journal of Chitwan Medical College 2021 19 Juin 2021;11(36):5.
  19. Bourguiba R DM, Savey L, Véronique H, Grateau G, Georgin-Lavialle S. Tolérance du vaccin anti-COVID-19 chez 190 patients adultes atteints de maladies auto-inflammatoires et inclus dans la JIR Cohorte. Rev Médecine Interne. 2021;42.

Most read articles by the same author(s)

1 2 > >>